This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Study to Evaluate the Efficacy and Safety of MEDI9...
Clinical trial

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

Read time: 2 mins
Last updated:13th Dec 2013
Identifier: NCT02054130

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma
Enrollment: 955
Actual Study Start Date: December 13, 2013
Study Completion Date: March 1, 2017
Primary Completion Date: December 12, 2016 (Final data collection date for primary outcome measure)

Arms:
- Placebo Comparator:
Placebo
- Experimental: MEDI9929 - Low Dose
- Experimental: MEDI9929 - Medium Dose
- Experimental: MEDI9929 - High Dose


Related journal: Tezepelumab in Adults with Uncontrolled Asthma.

Category Value
Date last updated at source 2017-04-13
Study type(s) Interventional
Expected enrolment 955
Study start date 2013-12-13
Estimated primary completion date 2016-12-12

View full details